Atrial fibrillation management in the hospital emergency department: 2012 update;Manejo de los pacientes con fibrilación auricular en los servicios de urgencias hospitalarios (actualización 2012)

Emergencias

Volumn 24, Issue 4, 2012, Pages 300-324

  Martín Martínez, Alfonso ^a   Fernández Lozano, Ignacio ^b   Coll Vinent Puig, Blanca ^a   Tercedor Sánchez, Luis ^b   Del Arco Galán, Carmen ^a   Arribas Ynsaurriaga, Fernando ^b   Suero Méndez, Coral ^a   Mont Girbau, Lluis ^b  

^a Sociedad Española de Medicina de Urgencias y Emergencias   (Spain)

^b Unidad de Gestión Clínica de Cardiología   (Spain)

Author keywords

Antiarrhythmic drugs; Anticoagulation; Atrial Fibrillation; Cardioversion; Emergency departments; Heart rate control; Stroke prevention

Indexed keywords

EID: 84865488095     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (190)

1. Feinberg WM, Blackshear JL, Lapaucis A, Kronmal R, Hart J. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:469-73.
2. Lip GYH, BeeversDG. History, epidemiology and importance of atrial fibrillation. Br Med J. 1995;311:1361-3.
3. The National Heart, Lung and Blood Institute working group on atrial fibrilllation: current understandings and research imperatives. J Am Coll Cardiol. 1993;22:1830-4.
4. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol. 1993;84:131R-138R.
5. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham Heart Study. Am Heart J. 1996;131:790-5.
6. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-9.
7. Miyasaka I, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhqyaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnnesota, 1980 to 2000. Circulation. 2006;114:119-25.
8. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Sticker BH, et al. Prevalence, incidence and lifetime risk for development of atrial fibrillation: The Rotterdam study. Eur Heart J. 2006;27:949-53.
9. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for management of atrial fibrillation. Eur Heart J. 2010;31:2369-429.
10. Thrall G, Lane D, Carroll D, Lyp GI. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448 e1-e19.
11. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andersen D, Davies DW, et al. Atrial fibrillationn management: a prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422-4.
12. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1995;92:835-41.
13. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for the development of atrial fibrillation: The Framingham heart study. Circulation. 2004;110:1042-6.
14. Le Heuzey JY, Paziaud O, Piot O, Said MA, Copie X, Lavergne T, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J. 2004;147:121-6.
15. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90:286-92.
16. Martín A, Merino JL, Arco C, Martínez Alday J, Laguna P, Arribas F, et al. Documento de consenso sobre el tratamiento de la fibrilación auricular en los servicios de urgencias hospitalarios. Rev Esp Cardiol. 2003;56:801-16.
17. Lip GYH, Golding DJ Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997;47:285-9.
18. Martín A, Aramburu FJ, Fernández C, Sousa MM, Cancio M, Caloto MT. Análisis de la contribución de los servicios de urgencias en España al manejo de la fibrilación auricular subsidiaria de restauración del ritmmo sinusal (Estudio RHYTHM-AF España). Murcia: Libro de Comunicaciones XXIII Congreso SEMES; 2011. pp. 81.
19. Laguna P, Martín A, Del Arco, Gargantilla P, on behalf of the GEFAUR-1 investigators. Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study. Ann Emerg Med. 2004;44:3-11.
20. Montero FJ, Calderón de la Barca JM, Jiménez Murillo l, Berlango A, Pérez I, Pérula L. Situación actual de los servicios de urgencias hospitalarios en España (II): Actividad asistencial, docente e investigadora. Emergencias. 2000;12:237-47.
21. Balanzó X, Pujol R. Estudio multicéntrico de las urgencias en hospitales generales básicos de Catalunya. Med Clin (Barc). 1989;92:86-90.
22. Del Arco C, Martín A, Laguna P, Gargantilla P. Analysis of current management of atrial fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med. 2005;46:424-30.
23. Coll-Vinent B, Junyent M, Orús J, Villarroel C, Casademont J, Miró O, et al. Tratamiento de la fibrilación auricular en los distntos niveles asistenciales de un área sanitaria. Med Cin (Barc). 2007;128:125-9.
24. Laguna P, Martín A, Del Arco C, Millán I, Gargantilla P. Differences among clinical classification schemes for predicting stroke in atrial fibrillation: implications for therapy in daily practice. Acad Emerg Med. 2005;12:828-34.
25. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba Follow-up Study. Am J Med. 1995;98:476-84.
26. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long term risks associated with atrial fibrillation: 20 year follow-up of the Renfrew-Paisley study. Am J Med. 2002;113:359-64.
27. Jung W, Luderitz B. Quality of life in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9(Supl):S177-S186.
28. Dorian P, Jung W, Newman D. The impairment of health-related quality of life in patients with intermitent atrial fibrillation: implications for the assesment of investigational therapy. J Am Coll Cardiol. 2000;36:1303-9.
29. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, et al. Atrial enlargement as a consecuence of atrial fibrillation. A prospective echocardiographic study. Circulation. 1990;82:792-7.
30. Goette A, Honeycutt C, Langberg JJ. Electrical remodelling in atrial fibrillation. Time course and mechanisms. Circulation. 1996;994:2968-74.
31. Wijjfels MCEF, Kirchof CJHJ, Dorland R, Alessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-68.
32. Zipes DP. Electrophysiological remodelling of the heart owing to rate. Circulation 1997;95:1745-1748.
33. Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol. 1998;82:10N-17N.
34. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomypathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-15.
35. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-5.
36. Hart RG, Halperin JL. Atrial fibrillation and stroke. Concepts and controversies. Stroke. 2001;32:803-8.
37. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
38. Hart RG, Pearce LA, Aguilar Ml. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.
39. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. Results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
40. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a metaanalysis. Ann Intern Med. 1999;131:492-501.
41. Urgencias en establecimientos con régimen de internado 2009. Ministerio de sanidad y política social (www.msps.es). (Consultado 30 Abril 2012). Disponible en http://pestadistico.msc.es/PEMSC25/Cubo. aspx?IdNodo=6375&InitCat=ESCRI&CubeName=Actividad en urgencias& CubeDescription=Actividad en urgencias.
42. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM for the CHS Colaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236-41.
43. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independient risks factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA. 1994;271:840-4.
44. Cameron A, Schwartz MJ, Kronmal RA, Kosinski AS. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol. 1988;61:714-7.
45. Omnen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Eng J Med. 1997;336:1429-34.
46. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence and predictors of atrial fibrillation in the Renfrew-Paisley study. Heart. 2001;86:516-21.
47. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneus conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998;31:588-92.
48. Hobs WJC, Fynn S, Todd DM, Wolfson P, Galloway M, Garrat CJ. Reversal of atrial electrical remodelling after cardioversion of persistent atrial fibrillation in humans. Circulation. 2000;101:1145-51.
49. Ricard P, Levy S, Trigano J, Paganelli F, Daoud E, Man KC, et al. Prospective assesment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol. 1997;79:815-6.
50. Reisinger J, Gatterer W, Lang W, Vanicek T, Eisserer G, Bachleitner T, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J. 2004;25:1318-24.
51. Arnold AZ, Mick MJ, Mazurek MP, Loop FD, Trohman RG. Role of prohylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation and flutter. J Am Coll Cardiol. 1992;19:851-5.
52. Zimetbaum P, Reynolds MR, Ho KKL, Graciano T, McDonald MJ, Maclennen S, et al. Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol. 2003;92:677-81.
53. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrilation on the risk of death: The Framingham Heart Study. Circulation. 1995;92:835-41.
54. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independient risk factor for stroke: The Framingham Heart Study. Stroke. 1991;22:983-8.
55. Wipf JE, Lipsky BA. Atrial fibrillation. Tromboembolic risk and indications for anticoagulation. Arch Intern Med. 1990;150:1598-603.
56. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31:967-75.
57. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin J. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000;35:183-7.
58. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-26.
59. Secondary prevention in non-rheumatic atrial fibrillation transient ischemic attack or minor stroke: EAFAT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-62.
60. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99:295-304.
61. Stroke in AF working group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546-54.
62. Go A, Hylek EM, Chang Y, Philips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-92.
63. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a new factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263-72.
64. Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001;87:346-9.
65. Singer DE, Chang Y, Fang MG, Borowsky LH, Pormenacki NK, Udaltsova N, et al. The net clinical Benedit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297-305.
66. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother. 2008;42:523-32.
67. Man-Son-Hing M, Anita Lau NG, Laupacis A. Choosing Antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-85.
68. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
69. Guyatt GH, Akl EA, Crowther M, Gutternau DD, Schuünemann MJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. Chest. 2012;141:7S-47S.
70. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
71. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al, for the AVERROES Steering Comité and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17.
72. Granger CB, Alexander AH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Eng J Med. 2011;365:981-92.
73. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet. 2007;370:493-503.
74. Sato H, Ishikawa K, Kitabatake A, Ogaea S, Maruyama Y, Yolota Y, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37:447-51.
75. Connolly SJ, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE. W): a randomized controlled trial. Lancet. 2006;367:1903-12.
76. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxismal atrial fibrillation. J Am Coll Cardiol. 1997;29:106-12.
77. Sparks PB, Jayaprakash S, Mond HG, Vohra JK, Grigg LE, Kalman JM. Left atrial mechanical function after brief duration atrial fibrillation. J Am Coll Cardiol. 1999;33:342-9.
78. Fatkin D, Kuchar DL, Thoburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307-16.
79. Oltrona L, Broccolina M, Merlini PA, Spinola A, Pezzano A, Mannucci PA. Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation. 1997;95:2003-6.
80. Lyp GY, Rumley A, Dunn FG, Lowe GD. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol. 1995;51:245-51.
81. Coll-Vinent B, Monteagudo J, Miró O, Marín, JL, Nava S, Scalise A, et al. Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation. Thrombosis Research. 2005;117:235-40.
82. Freestone B, Chong AY, Blann AD, Lip GYH. The effects of direct current cardioversion for persistent atrial fibrillationon indices of endothelial/ damage dysfunction. Thrombosis Research. 2006;118:479-85.
83. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126:15-20.
84. Elliott DJ, Zhao L, Jasper SE, Lieber EA, Klein AL, Weintraub WS. Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial. Am Heart J. 2008;156:374. e1-6.
85. Angeloni G, Alberti S, Romagnoli E, Banzato A, Formichi M, Cucchini U, Pengo V. Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study. Intern Emerg Med. 2011;6:117-23.
86. Naccarelli GV, Dell'Orfano JT, Wolbrete DL, Patel HM, Luck JC. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneus cardioversion, medical and direct current cardioversion, transesophageal ecocardiography, and antiembolic therapy. Am J Cardiol. 2000;85:36D-45D.
87. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, et al; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-20.
88. Murray RD, Deitcher SR, Shah A, Jasper SE, Bashir M, Grimm RA, et al. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing inmediate cardioversion from atrial fibrillation. J Am Soc Ecocardiography. 2001;14:200-8.
89. Schumacher B, Lüderitz B. Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Am J Cardiol. 1998;82:29N-36N.
90. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008;9:1181-9.
91. AFFIRM investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Eng J Med. 2002;347:1825-33.
92. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40.
93. Honhloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet. 2000;356:1789-94.
94. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomised trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-96.
95. Opolski G, Torbicki A, Kosior D, Szulc M, Wozakowska B, Kolodzief P, et al. Rate control vs rhythm control in patients with persistent nonvalvular atrial fibrillation: results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFÉ) study. Chest. 2004;126:476-86.
96. Denus S, Sanoski C, Carlssön J, Oploski G, Spinler SA. Rate vs rhythm control in atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165:258-62.
97. Bjerregaard P, Bailey WB, Robinson SE. Rate control in patients with chronic atrial fibrillation. J Am Coll Cardiol. 2003;41:1703-06.
98. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AL, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73.
99. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268-76.
100. Dronedarona: Conclusiones de su evaluación de riesgo beneficio. Agencia Española del Medicamento. (Consultado 30 Abril 2012). Disponible en: http://www.aemps.gob.es/informa/notasInformativas/ medicamentosUsoHumano/seguridad/2011/NI-MUH_16-2011.htm Referencia: SGMUH (FV), 16 /2011
101. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47-59.
102. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med. 1991;114:573-5.
103. Roberts SA, Diaz C, Nolan PE. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol. 1993;72:567-73.
104. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoota SH, Elkayam U. Efficacy and safety of medium and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during excerise in patients with chronic atrial fibrillation. Circulation. 1986;73:316-24.
105. Atwood JE, Myers JN, Sullivan MJ, Forbes SM, Pewen WF, Froelicher VF. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest. 1988;93:20-25.
106. Dibianco R, Morganroth J, Freitag JA, Ronan JA, Lindgren KM, Donohue DJ, et al. Effects of nadolol on the spontaneus and exerciseprovoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J. 1984;108:1121-7.
107. Eagle KA, Cannom DS, Garcia DA. Management of atrial fibrillation: translating clinical trial data into clinical practice. Am J Med. 2011;124:4-14.
108. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med. 1997;29:135-40.
109. Falk RH. Atrial Fibrillation. N Eng J Med. 2001;344:1067-78.
110. Khan IA. Single oral dosing of propafenone for pharmacological cardioversion of recent onset atrial fibrillation. J Am Colll Cardiol. 2001;37:542-7.
111. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-13.
112. Friberg L, Hammar N, Edvarsson N, Rosenquist M. The prognosis of patients with atrial fibrillation is improved when sinus rhythm is restored: report from the Stockholm cohort of atrial fibrillation (SCAF). Heart. 2009;95:1000-5.
113. Hohnloser S, Crijns HJGM, Van Eickels M, Gandin P, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-78.
114. Calkins H, Reynolds MR, Spector P. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation. Two systematic literature reviews and meta-analyses. Circ Arrhythmia Electrophysiol. 2009;2:349-61.
115. Parkash R, Tang AS, Sapp JL, Wells GJ. Approach to the Catheter Ablation Technique of Paroxysmal and Persistent Atrial Fibrillation: A Meta-Analysis of the Randomized Controlled Trials. J Cardiovasc Electrophysiol. 2011;22:729-38.
116. Cossio FJ, Alliot E, Botto GL, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace. 2008;10:21-7.
117. Kirchhof P, Blomstrom-Lundquisqt C, Calkins H, Camm AJ, Cappato R, Cosio F, et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled "research perspectives on atrial fibrillation". Europace. 2009;11:860-95.
118. Lip GYH, Tse HF. Management of atrial fibrillation. Lancet. 2007;370:604-18.
119. Savalieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhytmic drugs, investigational agents and innovative approaches. Europace. 2008;10:647-65.
120. Reiffel JA. Rate versus rhythm control pharmacotherapy for atrial fibrillation: where are we in 2008? J Atr Fibrillation. 2008;1:31-47.
121. Burashnikhov A, Antzelevitch C. Advances in the pharmacological treatment in atrial fibrillation. Curr Med Lit Cardiol. 2010;29:1-5.
122. Schilling RJ. Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs. Heart. 2010;5:333-8.
123. Desbiens NA. Should all patients with atrial fibrillation be screened with echocardiography? J Gen Intern Med. 1992;7:131-9.
124. Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 201!;13:161-73.
125. Capucci A, Lenzi T, Boriani GM, Trisolino G, Binetti N, Cavazza L, et al. Effectiveness of loading oral flecainide for converting recent onset atrial fibrillation to sinus rhythm in patients without organic heart disease or only systemic hypertension. Am J Cardiol. 1992;70:69-72.
126. Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000;86:950-3.
127. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SV. Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation. Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998;98:2574-9.
128. Pedersen OD. Restoration and Maintenance of Sinus Rhythm in Patients With Left Ventricular Dysfunction and Atrial Fibrillation/Flutter is Associated With Improved Survival. A DIAMOND Substudy. J Am Coll Cardiol. 2001;37:1A-648A.
129. Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538-45.
130. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboaul P, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol. 2003;41:255-62.
131. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, García-Dorado D, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomised, controlled study. J Am Coll Cardiol. 1996;27:1079-82.
132. Donovan KD, Power BM, Hockings BE, Dobb GJ, Leek Y. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995;75:693-7.
133. Boriani G, Bifft G, Capucci A, Botto G, Broffoni T, Ongari M, et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol. 1998;21:2470-4.
134. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recentonset atrial fibrillation. J Am Coll Cardiol. 2011;57:313-21.
135. Falk RH. Proarrhythmia in patients treated for atrial fibrillation and flutter. Ann Intern Med. 1992;117:141-50.
136. Michael JA, Stiell IG, Agarwall S, Mandavia DP. Cardioversion of paroxysmal atrial fibrillation in the emergency deparment. Am J Emerg. Med. 1999;33:379-87.
137. Mittal S, Ayati S, Stein K, Schwartzman D, Caulovinch D, Tchau PJ, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sinus wave monophasic shocks. Circulation. 2000;101;1282-87.
138. Gallagher MM, Yap YG, Padula M, Ward DE, Rowland E, Camm AJ. Arrhythmic complications of electrical cardioversion: relationship with shoc energy. Int J Cardiol. 2008;123:307-12.
139. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913.
140. Alegret JM, Viñolas X, Grande A, Castellanos E, Asso A, Tercedor L, et al. Utilidad en la práctica clínica del tratamiento antiarrítmico tras cardioversión eléctrica en pacientes sin cardiopatía estructural. Rev Esp Cardiol. 2008;61:1274-9.
141. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719-28.
142. Kaufman ES, Zimmermann PA, Wang T. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: a multivariate analysis. J Am Coll Cardiol. 2004;44:1276-82.
143. Alboni P, Botto GL, Baldi N. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351:2384-91.
144. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhytmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-12.
145. Vorperian VR, Havighurst TC, Miller S, Jannuary CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30:791-8.
146. Roden DM. Proarrhythmia as a pharmacogenomic entity: A critical review and formulation of a unifying hypothesis. Cardiovasc Res. 2005;67:419-25.
147. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121:1047-60.
148. Wood MA, Brown-Mahoney C, Kay, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101:1138-44.
149. Bradley DJ, Shen WK. Atrioventricular junction ablation combined with either right ventricular pacing or cardiac resynchronization therapy for atrial fibrillation: the need for large-scale randomized trials. Heart Rhythm. 2007;4:224-32.
150. Nair GM, Nery PB, Diwakaramenon S, Healey JS, Connolly SJ, Murillo CA. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2009;20:138-44.
151. Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM, et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol. 2009;2:626-33.
152. Bhargava M, Di Biase L, Mohanty P, Prasad S, Martin DO, Williams-Andrews M, et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm. 2009;6:1403-12.
153. Singh BN, Singh SN, Reda DJ. Amiodarone versus sotalol for atrial fibrillation. New Engl J Med. 2005;352:1861-72.
154. Kääb S, Hinterseer M, Näbauer M, Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilt study using i.v. sotalol. Eur Heart J. 2003;24:649-57.
155. Kirchhoff P, Franz MR, Bardai A, Wiede E. Giant T-U waves precede torsades de pointes in long QT symdrome. A systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol. 2009;54:143-9.
156. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025-34.
157. Singh SN, Fletcher RD, Fisher SG. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77-82.
158. Kirchhoff P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in long QT symdrome. A systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol. 2009;54:143-9.
159. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A Short-Term, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol. 2010;21:597-605.
160. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54:1089-95.
161. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns M, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-87.
162. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-99.
163. Singh D, Cingolani E, Diamon GA, Kaul S. Dronedarone for atrial fibrillation: have we expanded the antiarrhythmic armamentarium. J Am Coll Cardiol. 2010;55:1569-76.
164. Savelieva I, Camm AJ. Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? Am Heart J. 2007;154:403-6.
165. Schneider MP, Hua TA, Bohm M, Wachtell SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299-307.
166. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-39.
167. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15:36-43.
168. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152:217-22.
169. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggiom AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;151:985-91.
170. Wachtell K, Lehto M, Gerdts E, Olsen MM, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-9.
171. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403-11.
172. Schneider MP, Hua TA, Bohm M, Wuchtell SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299-307.
173. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006;27:1841-6.
174. Belluzzi F, Sernesi L, Preti P. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol. 2009;53:24-9.
175. Savelieva I, Camm AJ. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5:30-41.
176. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol. 2010;381:1-13.
177. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Lovino E, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114:1455-61.
178. Song YB, On YK, Kim JH. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J. 2008;156:373.
179. Liakopoulos OJ, Choi YH, Kuhn EW. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg. 2009;138:678-86.
180. Kourliouros A, Valencia O, Tavakkoli Hosseini M, May R, Sarsan M, Camm J, et al. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery. J Thorac Cardiovasc Surg. 2011;141:244-8.
181. Almroth H, Hoglund N, Boman K, Englund A, Jensen S, Kjellman B, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J. 2009;30:827-33.
182. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty C. Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51:828-35.
183. Liu T, Li L, Korantzopoulos P, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126:160-70.
184. Savelieva I, Camm AJ. Statins and atrial fibrillation: do we need a further study?. Expert Rev Cardiovasc Ther. 2011;9:801-4.
185. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13:308-28.
186. Savelieva I, Camm AJ. Fish Oil for Secondary Prevention of Atrial Fibrillation: Should We Still Believe in Its Antiarrhythmic Effect? Circulation. 2011;124:1093-6.
187. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion: A Prospective, Randomized Study. Circulation. 2011;124:1100-6.
188. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004;25:1100-7.
189. Krishnan GM, Sood NA, Coleman CI. Intravenous corticosteroide use is associated with reduced early recurrence of atrial fibrillation followin radiofrequency catheter ablation. J Am Coll Cardiol. 2010;55:1136-150.
190. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace. 2011;13:610-25.